Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
Michael LehrkeAnja VogtVolker J J SchettlerMatthias GirndtUwe FraassAnja Tabbert-ZitzlerIan BridgesNafeesa N DhalwaniKausik K RayPublished in: Advances in therapy (2024)
ClinicalTrials.gov Identifier NCT02770131 (registration date 27 April 2016).